Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.73 |
| ▸ | LCK | P06239 | 11/20 | 0.71 |
| ▸ | FYN | P06241 | 11/20 | 0.71 |
| ▸ | YES1 | P07947 | 11/20 | 0.71 |
| ▸ | KDR | P35968 | 11/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.71 |
| ▸ | AURKA | O14965 | 3/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5396583 | 0.97 | SRC (0.74) | SRCLCKFYNYES1KDR | |
| SCHEMBL5401516 | 0.91 | SRC (0.69) | SRCLCKFYNYES1KDR | |
| SCHEMBL5414900 | 0.90 | SRC (0.75) | SRCLCKFYNYES1KDR | |
| SCHEMBL5403257 | 0.88 | SRC (0.71) | SRCLCKFYNYES1KDR | |
| SCHEMBL6803608 | 0.87 | SRC (0.74) | SRCLCKFYNYES1KDR | |
| SCHEMBL5410896 | 0.87 | SRC (0.62) | SRCLCKFYNYES1KDR | |
| SCHEMBL6798174 | 0.86 | SRC (0.85) | SRCLCKFYNYES1KDR | |
| SCHEMBL6701453 | 0.84 | SRC (0.83) | SRCLCKFYNYES1KDR | |
| SCHEMBL6697574 | 0.84 | SRC (0.86) | SRCLCKFYNYES1KDR | |
| SCHEMBL6692770 | 0.84 | SRC (0.98) | SRCLCKFYNYES1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157577-B2 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | SUGEN INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204407-A1 | 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors | DMPK, MAP3K20, PHKG1 | SRC 297/4885LCK 143/4885FYN 489/4885 |
| US-20040266843-A1 | Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) | CHEK2, CHEK1, ATM | SRC 663/4885LCK 890/4885FYN 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.